How do you pay?

How to pay the least

Ask for the cash price

Neupogen

Neupogen is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Neupogen’s cash price, and one or two other pharmacies too.
  2. Neupogen’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameNeupogen
Authorized genericfilgrastim
Regular genericfilgrastim
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Neupogen?
The original
–
–

Brand nameThe maker’s card

Amgen SupportPlus Co-Pay Program

Savings card from Amgen

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on amgensupportplus.com 

Or call 1-866-264-2778.

In the maker’s words

“Pay as little as $0 out-of-pocket for each dose or cycle…”

From the maker’s offer on amgensupportplus.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Neupogen itself, from the same company, sold without the brand name, and usually for less. For now Neupogen is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Neupogen is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

NEUPOGEN is a leukocyte growth factor indicated to

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
  • Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
  • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
  • Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Source: the FDA label for Neupogen (Amgen, Inc), July 23, 2026. Full label on DailyMed 

Good to know